Evaluation of 27 Parkinson’s Disease Algerian Patients who Underwent DBS at the STN level: Clinical and Genetic Aspect to using Multiple Correspondence Analysis
M. Sayad1,2, M. Zouambia1, M. Chaouche3, M. Nebbal4, M. Bendini4, S. Lesage5, A. Brice5, M. Brahim Errahmani6, B. Asselah1
1. Laboratory of Behavioral and cognitive Neuroscience, Faculty of Biological Sciences, University of Science and
Technologiy « Houari Boumedienne, Algiers, Algeria.
2. Department of Biology, Faculty of natural sciences and life, University of Blida 1, Algeria.
3. Department of Neurology, Ben Aknoun Hospital, Algiers, Algeria.
4. Department of Neurochirurgy, Central Army « Mohamed Seghir Nekkache », Algiers, Algeria.
5. INSERM UMR_S975 (formerly UMR_S679), Departement of Genetics, Cytogenetic and Embryology, Pitié-
Salpetrière Hospital, Paris, France.
6. Department of Chimie, University of BLIDA 1, Algeria.


The statistical comparative study between the clinical charts of gene LRRK2 mutation G2019S-bearing
patients compared to non bearers of that mutation among 27 patients with Parkinson disease (PD)
having undergone Deep Brain Stimulation (DBS) at the level of the Subthalamic nucleus (SN) has
shown considerable improvement of motor UPDRS III (Unified Parkinson’s Disease Rating Scale III),
Hoehn and Yahr Scale (H and Y Scale) and Schwab and England’s activities of daily living scale (S
and E scale) in situation of medication and stimulation. This shows the efficiency of surgical treatment
in association with dopaminergic agonist regardless of the presence or absence of mutation G2019S
among those patients. However, dyskinesia appear earlier among groups of mutation bearers compared
to non bearers. The Multiple Correspondence Analysis (MCA) has revealed that patients who bear and
those who do not bear this mutation show two different clinical charts. In fact, patients bearing the
mutation have a mixed form with prevailing left side asymmetry and a strong aggravation of the disease
regardless of the patient’s gender. The second group of patients who do not bear the mutation shows
some differences compared to the clinical chart depending on the gender. In this latter group, men are
from non consanguine families with an age category between 60 and 70 years, developing the disease
later than women (40 to 70 years). However, women not bearing mutation G2019S have a consanguity
with PD family antecedents, an age category between 50 and 60 develop the disease earlier (20-40
years) and an akineto-rigid form with left side prevailing asymmetry.